Logo image of WVE

WAVE LIFE SCIENCES LTD (WVE) Stock Fundamental Analysis

NASDAQ:WVE - Nasdaq - SG9999014716 - Common Stock - Currency: USD

6.7  -0.13 (-1.9%)

Fundamental Rating

3

WVE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. The financial health of WVE is average, but there are quite some concerns on its profitability. WVE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

WVE had negative earnings in the past year.
In the past year WVE has reported a negative cash flow from operations.
WVE had negative earnings in each of the past 5 years.
WVE had a negative operating cash flow in each of the past 5 years.
WVE Yearly Net Income VS EBIT VS OCF VS FCFWVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

WVE has a Return On Assets of -38.96%. This is comparable to the rest of the industry: WVE outperforms 45.64% of its industry peers.
The Return On Equity of WVE (-62.52%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -38.96%
ROE -62.52%
ROIC N/A
ROA(3y)-53%
ROA(5y)-54.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WVE Yearly ROA, ROE, ROICWVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for WVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WVE Yearly Profit, Operating, Gross MarginsWVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

WVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
WVE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, WVE has more shares outstanding
There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
WVE Yearly Shares OutstandingWVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
WVE Yearly Total Debt VS Total AssetsWVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

WVE has an Altman-Z score of -0.23. This is a bad value and indicates that WVE is not financially healthy and even has some risk of bankruptcy.
WVE has a Altman-Z score of -0.23. This is comparable to the rest of the industry: WVE outperforms 53.33% of its industry peers.
WVE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.23
ROIC/WACCN/A
WACC9.79%
WVE Yearly LT Debt VS Equity VS FCFWVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.95 indicates that WVE has no problem at all paying its short term obligations.
WVE's Current ratio of 2.95 is in line compared to the rest of the industry. WVE outperforms 51.28% of its industry peers.
WVE has a Quick Ratio of 2.95. This indicates that WVE is financially healthy and has no problem in meeting its short term obligations.
WVE has a Quick ratio of 2.95. This is comparable to the rest of the industry: WVE outperforms 55.90% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.95
WVE Yearly Current Assets VS Current LiabilitesWVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

WVE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -61.54%.
Looking at the last year, WVE shows a decrease in Revenue. The Revenue has decreased by -7.06% in the last year.
WVE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 46.63% yearly.
EPS 1Y (TTM)-61.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.83%
Revenue 1Y (TTM)-7.06%
Revenue growth 3Y38.28%
Revenue growth 5Y46.63%
Sales Q2Q%-26.82%

3.2 Future

WVE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.08% yearly.
WVE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 47.70% yearly.
EPS Next Y-31.33%
EPS Next 2Y-15.11%
EPS Next 3Y5.2%
EPS Next 5Y20.08%
Revenue Next Year13.8%
Revenue Next 2Y7.71%
Revenue Next 3Y40.14%
Revenue Next 5Y47.7%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
WVE Yearly Revenue VS EstimatesWVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
WVE Yearly EPS VS EstimatesWVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for WVE. In the last year negative earnings were reported.
Also next year WVE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WVE Price Earnings VS Forward Price EarningsWVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WVE Per share dataWVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.11%
EPS Next 3Y5.2%

More info and screens

0

5. Dividend

5.1 Amount

WVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WAVE LIFE SCIENCES LTD

NASDAQ:WVE (6/25/2025, 10:30:05 AM)

6.7

-0.13 (-1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners84.98%
Inst Owner Change2.58%
Ins Owners0.53%
Ins Owner Change6.72%
Market Cap1.03B
Analysts83.53
Price Target21.51 (221.04%)
Short Float %11.66%
Short Ratio10.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)91.22%
Min EPS beat(2)-10.05%
Max EPS beat(2)192.48%
EPS beat(4)1
Avg EPS beat(4)24.61%
Min EPS beat(4)-64.24%
Max EPS beat(4)192.48%
EPS beat(8)4
Avg EPS beat(8)37.62%
EPS beat(12)5
Avg EPS beat(12)-23.12%
EPS beat(16)6
Avg EPS beat(16)-15.36%
Revenue beat(2)1
Avg Revenue beat(2)85.03%
Min Revenue beat(2)-25.7%
Max Revenue beat(2)195.76%
Revenue beat(4)1
Avg Revenue beat(4)1.33%
Min Revenue beat(4)-144.85%
Max Revenue beat(4)195.76%
Revenue beat(8)4
Avg Revenue beat(8)36%
Revenue beat(12)4
Avg Revenue beat(12)-3.47%
Revenue beat(16)5
Avg Revenue beat(16)-0.59%
PT rev (1m)-1.94%
PT rev (3m)-7.97%
EPS NQ rev (1m)-2.77%
EPS NQ rev (3m)-3.05%
EPS NY rev (1m)-4.72%
EPS NY rev (3m)2.68%
Revenue NQ rev (1m)-0.94%
Revenue NQ rev (3m)-8.56%
Revenue NY rev (1m)-8.49%
Revenue NY rev (3m)-12.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.84
P/FCF N/A
P/OCF N/A
P/B 5.75
P/tB 5.75
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0.68
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.96%
ROE -62.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53%
ROA(5y)-54.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.4%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 2.95
Altman-Z -0.23
F-Score2
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)22.36%
Cap/Depr(5y)18.22%
Cap/Sales(3y)13.04%
Cap/Sales(5y)9.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.83%
EPS Next Y-31.33%
EPS Next 2Y-15.11%
EPS Next 3Y5.2%
EPS Next 5Y20.08%
Revenue 1Y (TTM)-7.06%
Revenue growth 3Y38.28%
Revenue growth 5Y46.63%
Sales Q2Q%-26.82%
Revenue Next Year13.8%
Revenue Next 2Y7.71%
Revenue Next 3Y40.14%
Revenue Next 5Y47.7%
EBIT growth 1Y-74.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.97%
EBIT Next 3Y-16.01%
EBIT Next 5YN/A
FCF growth 1Y-4399.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7457.87%
OCF growth 3YN/A
OCF growth 5YN/A